SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Athira Pharma, Inc. (ATHA) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+166.7%).
- 分析师共识目标价 $18.00 (+166.7% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 48/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ATHA
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-24.70
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$18.00 (+166.7%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2018 |
$-1,562,570.00 |
$0.00 |
$-5.1M |
- |
| 2019 |
$-0.14 |
$0.00 |
$-4.7M |
- |
| 2020 |
$-0.57 |
$0.00 |
$-18.63M |
- |
| 2021 |
$-1.47 |
$0.00 |
$-54.37M |
- |
| 2022 |
$-2.31 |
$0.00 |
$-87.26M |
- |
| 2023 |
$-3.09 |
$0.00 |
$-117.67M |
- |
| 2024 |
$-2.52 |
$0.00 |
$-96.94M |
- |
| 2025 |
$-24.70 |
$0.00 |
$-105.61M |
- |
